The TRIUMPH-4 trial showed that retatrutide at 12mg reduced: Systolic blood pressure: 14.0 mmHg reduction Non-HDL cholesterol: clinically meaningful improvement High-sensitivity C-reactive protein: significant reduction (a marker of systemic inflammation) Triglycerides: substantial decrease Tirzepatide produces similar cardiovascular improvements, with well-documented reductions in blood pressure, triglycerides, and inflammatory markers across the SURMOUNT and SURPASS programs
Starting at a low dose allows for the minimization of negative side effects
F.MitreaL.VodnarD
MT-II also searched as Melanotan 2 acts across multiple melanocortin receptors and is studied for two of the most-researched outcomes in melanocortin research: melanin synthesis and libido modulation
Oxford University Press Harirchian MH, Babaie S, Keshtkaran N, Bitarafan S (2023) The association of serum carnitine levels with severity of fatigue in patients with multiple sclerosis: a pilot study
Novo Nordisk rose as much as 4% after England's drug price watchdog recommended the use of its best-selling drug Wegovy to prevent heart attacks and strokes, marking the first GLP-1 backed for this use in the country